Eliaz Therapeutics
Eliaz Therapeutics, with a valuation of $49.5 million, is raising funds on Wefunder. The business has created a life-saving medical device to fight against sepsis. Eliaz Therapeutics’ XGal-3 is designed to halt sepsis progression by targeting Galectin-3, a protein that drives the deadly inflammatory process. The innovative technology behind XGal-3 is protected by 60 patents across 34 countries and has potential applications beyond sepsis, including cancer and kidney disease. Isaac Eliaz founded Eliaz Therapeutics in September 2015. The current crowdfunding campaign has a minimum target of $50,000 and a maximum target of $1.24 million. The campaign proceeds will be used for product development, QA and regulatory activities, ligand development, clinical and strategy readiness, and general and administrative expenses.
Eliaz Therapeutics, with a valuation of $49.5 million, is raising funds on Wefunder. The business has created a life-saving medical device to fight against sepsis. Eliaz Therapeutics’ XGal-3 is designed to halt sepsis progression by targeting Galectin-3, a protein that drives the deadly inflammatory process. The innovative technology behind XGal-3 is protected by 60 patents across 34 countries and has potential applications beyond sepsis, including cancer and kidney disease. Isaac Eliaz founded Eliaz Therapeutics in September 2015. The current crowdfunding campaign has a minimum target of $50,000 and a maximum target of $1.24 million. The campaign proceeds will be used for product development, QA and regulatory activities, ligand development, clinical and strategy readiness, and general and administrative expenses.
Stay in the Loop
Get updates from Eliaz Therapeutics
Get exclusive updates from Eliaz Therapeutics
Be the first to know about company milestones, news, and opportunities.
đź”’ No spam. Just real progress.
Company Stats
Key metrics about Eliaz Therapeutics
Are you the owner of Eliaz Therapeutics?
Claim your company profile to respond to reviews, update your information, and connect with investors.
Claim This Company